{
    "paper_id": "47396ffdb75ec6e62302811d1053b6592e74f991",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": ". See also Polymorphonuclear leukocytes (PMNs). resident macrophages, 197-198, 200f innate recognition, 187-192 overviews of, 187, 191-192 pattern recognition receptors (PRRs), 187-192, 190f . See also Pattern recognition receptors (PRRs 1103 -1104 , 1103t increased, 1096 , 1101 -1104 , 1101f, 1103t, 1111 -1114 mechanisms of, 1103 -1104 , 1103t outcomes of, 1115 -1116 pathophysiology of, 1102 -1103 treatment of, 1111 -1114 hypothesis, 1100 -1101 lung, 1537 Permissive hypercapnia, 131, 1528 .",
            "cite_spans": [
                {
                    "start": 57,
                    "end": 138,
                    "text": "macrophages, 197-198, 200f innate recognition, 187-192 overviews of, 187, 191-192",
                    "ref_id": null
                },
                {
                    "start": 177,
                    "end": 190,
                    "text": "187-192, 190f",
                    "ref_id": null
                },
                {
                    "start": 238,
                    "end": 242,
                    "text": "1103",
                    "ref_id": null
                },
                {
                    "start": 243,
                    "end": 248,
                    "text": "-1104",
                    "ref_id": null
                },
                {
                    "start": 249,
                    "end": 272,
                    "text": ", 1103t increased, 1096",
                    "ref_id": null
                },
                {
                    "start": 273,
                    "end": 279,
                    "text": ", 1101",
                    "ref_id": null
                },
                {
                    "start": 280,
                    "end": 285,
                    "text": "-1104",
                    "ref_id": null
                },
                {
                    "start": 286,
                    "end": 306,
                    "text": ", 1101f, 1103t, 1111",
                    "ref_id": null
                },
                {
                    "start": 307,
                    "end": 312,
                    "text": "-1114",
                    "ref_id": null
                },
                {
                    "start": 313,
                    "end": 332,
                    "text": "mechanisms of, 1103",
                    "ref_id": null
                },
                {
                    "start": 333,
                    "end": 338,
                    "text": "-1104",
                    "ref_id": null
                },
                {
                    "start": 339,
                    "end": 364,
                    "text": ", 1103t outcomes of, 1115",
                    "ref_id": null
                },
                {
                    "start": 365,
                    "end": 370,
                    "text": "-1116",
                    "ref_id": null
                },
                {
                    "start": 371,
                    "end": 395,
                    "text": "pathophysiology of, 1102",
                    "ref_id": null
                },
                {
                    "start": 396,
                    "end": 401,
                    "text": "-1103",
                    "ref_id": null
                },
                {
                    "start": 402,
                    "end": 420,
                    "text": "treatment of, 1111",
                    "ref_id": null
                },
                {
                    "start": 421,
                    "end": 426,
                    "text": "-1114",
                    "ref_id": null
                },
                {
                    "start": 427,
                    "end": 443,
                    "text": "hypothesis, 1100",
                    "ref_id": null
                },
                {
                    "start": 444,
                    "end": 449,
                    "text": "-1101",
                    "ref_id": null
                },
                {
                    "start": 450,
                    "end": 460,
                    "text": "lung, 1537",
                    "ref_id": null
                },
                {
                    "start": 461,
                    "end": 494,
                    "text": "Permissive hypercapnia, 131, 1528",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "See also Hypercapnia. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "-related",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1297--1298",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Severe acute respiratory syndrome (SARS)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Severe asthma",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "793--794",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Severe fibrothorax, 1460.e5f. See also Fibrothorax",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Severe (morbid) obesity, 1719. See also Obesity. SFTs, Solitary fibrous tumors (SFTs) SHH signaling. See Sonic hedgehog (SHH) signaling",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "709 Shock lung",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Shigella Spp",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Shprintzen syndrome, 864-865 Shrinking lung syndrome",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1178--1179",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "See Sclerosing hemangiomas (SHs). Shunts",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Shs",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "66--67",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Siadh",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Sibilant rhonchus",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "271--272",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "308.e1 Sighing breathing patterns",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sieverts",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "270",
            "issn": "",
            "pages": "259--260",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Silent nociceptors",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Simian virus (SV40)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Single-breath method, 65 tests",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Single gene disorders",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Single-lung transplantation (SLT), 1836. See also Lung transplantation. Single-lung units",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Single nucleotide polymorphisms (SNPs)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "34--36",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Single-photon emission computed tomography (SPECT)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Single-photon emission computed tomography-ventilation perfusion imaging",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Sinusoid sign",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Six-minute walk distance (6MWD)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Six-minute walk tests (6MWTs)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "See also Connective tissue diseases (CTDs). clinical features of, 1180 definition of, 1180 diffuse lung disease in, 1180 epidemiology of, 1180 pulmonary manifestations of",
            "authors": [],
            "year": null,
            "venue": "Sj\u00f6gren syndrome",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "tracheobronchial disease in, 1180-1181 Skeletal abnormalities",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Skin and subcutaneous lesions, 275.e1",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "275",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Sleep and sleep disorders breathing control during sleep, 1511-1526 kidney disease and, 1650-1651 obstructive sleep apnea (OSA), 1552-1568 sleep disruption consequences",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sle",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1547--1551",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Slope (rise) adjusters, 1776. See also Mechanical ventilation (MV)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Slowly adapting stretch receptors (SARs)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Slowly growing mycobacteria, 630t, 636. See also Nontuberculous mycobacterial (NTM) infections. comparisons of, 630t definition of",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Mycobacterium kansasii pulmonary disease",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Mycobacterium malmoense",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "640--641",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Sniff tests",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "433",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Snorkeling dendritic cells (DCs)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Single nucleotide polymorphisms (SNPs)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Snps",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Social histories, 268-269. See also Medical interviews",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Social psychological analyses",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "264--265",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Social Security Disability Insurance (SSDI) program, 478.e2-478.e3",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "478",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Sodium diazobenzene sulfate exposures, 1154 Solid organ transplants (SOTs) cryptococcosis impacts on",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "See also Extrapulmonary disorders",
            "authors": [],
            "year": null,
            "venue": "Solid organ vs. stem cell transplantation",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Solitary papillomas",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Soluble guanylyl cyclase activators",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Somatic pain",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "515--516",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Sonic hedgehog (SHH) signaling",
            "authors": [],
            "year": null,
            "venue": "Somatostatin receptors (SSTRs)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Sonorous rhonchus",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "271--272",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "See Solid organ transplants (SOTs)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sots",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Spasmodic croup",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "530--531",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Specific-inhalation challenge (SIC) tests, 1297 Specimens adequacy of, 283-284 collection of, 279-283 selection of",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "279--283",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Single-photon emission computed tomography (SPECT)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Spect",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Spectator ions",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Single-photon emission computed tomography-ventilation perfusion imaging (SPECT V/Q). Speech pathology management, 511 Spinal cord diseases",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Spect V/Q",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1694--1695",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Spiral computed tomography (CT)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "304--305",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Spiritual and emotional support",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1815--1816",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Splanchnic effects",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "See Solitary pulmonary nodules (SPNs). Spontaneous bacterial pleuritis",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Spns",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "See also Cough. Spontaneous pneumothorax",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "See also Endemic mycoses",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sporotrichosis",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "659--660",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "SPRY) proteins, 26 SPRY proteins. See Sprouty (SPRY) proteins. Sputum cytology, 948 examinations",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sprouty",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "561--562",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Social Security Administration (SSA)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Ssa",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "See Systemic sclerosis (SSc)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "See Social Security Disability Insurance (SSDI) program",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Ssdi Program",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "See Secondary spontaneous pneumothorax (SSP)",
            "authors": [],
            "year": null,
            "venue": "SSP",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "See Somatostatin receptors (SSTRs)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sstrs",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "23f. See also Lung growth and development. alveolar stage",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "See also Tumor-node-metastasis (TNM) staging",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Staging",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "See also Invasive staging techniques. non-small cell lung cancer (NSCLC)",
            "authors": [],
            "year": null,
            "venue": "carcinomas, 964.e1f-964.e2f invasive techniques",
            "volume": "364",
            "issn": "",
            "pages": "952--956",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Standard diagnostic bronchoscopy, 374-379, 374f-375f. See also Diagnostic bronchoscopy",
            "authors": [],
            "year": null,
            "venue": "vs. restaging, 369.e1t Standard deviation, geometric",
            "volume": "",
            "issn": "",
            "pages": "360--361",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "State workers' compensation, 478.e3 Static conditions",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "78--84",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Embolectomy, pulmonary, 1021-1022 Embryonic stage, 22-24, 23f. See also Lung growth and development. EMG. See Electromyography (EMG). EMN. See Electromagnetic navigation (EMN). Emotional and spiritual support, 1815-1816 ethical and legal justifications for, 1809-1813, 1809t medical futility, 1811-1812 palliative care justifications, 1812-1813 medical decision-making models of, 1813-1814 overviews of, 1807, 1820b patient and family needs considerations, 1815, 1815t quality of life (QOL) considerations of, 1814 references for, 1820 respiratory failure outcomes predictions, 1807-1808 Acute Physiology and Chronic Health Evaluation (APACHE), 1807 prognosis factors, 1807-1808 Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatment (SUPPORT), 1807 settings for, 1808-1809, 1815-1816 Environmental aerosols, 180-183. See also Aerosol deposition and clearance. dust mite fecal aerosols, 181 filtration masks and, 181-182 infectious aerosols, 181-183, 182f nanoparticles and, 180-181 pulmonary tuberculosis (TB) and, 181 smog and, 180-181 tobacco smoke and, 181 See Eosinophilic pneumonia (EP). Epicoccum spp., 1153-1154 normal airway mucins, 157-158 obstructive airway diseases, 164-166 overviews of, 157, 167b references for, 167 alveolar. See also Alveolar epithelium. fluid transport, 150-156 pulmonary surfactant and, 134-149 lung, branching, 22-24 Epitopes, 603 Epoch, cough, 497-498, 498f. See also Cough. EPP. See Extrapleural pneumonectomy (EPP). Epsilon toxin (Clostridium perfringens), 709 Epstein-Barr virus (EBV), 529-530, 529t, 1475-1476 Equal pressure point theory, 86, 86f Equations. See Laws-constants-equations. Equilibrium, 112. See also Acid-base balance. Equipment, clinical exercise testing, 451 Ergot alkaloids, 1421 ERK. See Extra-cellular signal-regulated kinase (ERK). ERK pathways, 1246 Erlotinib (Tarceva), 1284 ERV. See Expiratory reserve volume (ERV). Erythema nodosum, 1189-1190, 1195f, 1195t, 1200 ESAT-6, 593 Escherichia coli O157:H7, 709 Esophageal balloons, 435.e4f Esophageal perforations, 1415-1416, 1415f Estrogen-containing medications, 1255 EsxH (TB10.4) protein, 599 ET-1 antagonists. See Endothelin-1 (ET-1) antagonists. Ethical and legal justifications, 1809-1813, 1809t. See also End-of-life care. Ethionamide, 628.e13-628.e18, 628. e14t-628.e15t Ethnicity and race trends, 927-928 Etoposide (VP-16), 1282 European Community Respiratory Health Survey, 1301-1302 EUS. See Endoscopic ultrasound (EUS). Expected future medical treatment, 478.e1 Expectorants, 513. See also Antitussives. Experimental pneumonia, 1542 Entities, borderline (Continued) Exudative pleural effusion (PE), 1402-1405. See also Pleural effusion (PE). abdominal diseases and, 1415-1418 abdominal surgery and, 1417 acute pancreatitis and, 1416 asbestos exposures and, 1419 bacteriologic stains for, 1405 bilious pleural effusion (PE), 1418 catheters, misplaced, 1424, 1424.e5f chronic pancreatic pleural effusion (PE), 1416-1417 collagen vascular diseases and, 1419 cultures for, 1405 definition of, 1414 drug reactions, induced, 1421-1422 endometriosis and, 1422 esophageal perforations and, 1415-1416, 1415f Fontan procedure for, 1421 inflammatory diseases and, 1418-1419 intra-abdominal abscesses and, 1417 lactate dehydrogenase (LDH) and, 1396-1397, 1403 lupus pleuritis and, 1418-1419 Meigs syndrome and, 1422 ovarian hyperstimulation syndrome and, 1422 pancreatic ascites and, 1417 pancreatic disease and, 1416-1417 pleural fluid. See also Pleural fluid. appearance of, 1403 cell counts, differential, 1403-1404 cell counts, white cells, 1403-1404 cytology of, 1404 glucose in, 1403 protein in, 1403 post-cardiac injury syndrome (PCIS) and, 1420, 1424.e4f post-coronary artery bypass surgery (CAGB) and, 1420-1421 pulmonary embolism (PE) and, 1414-1415, 1414f rheumatoid arthritis (RA) and, 1176, 1424. e3f rheumatoid pleuritis and, 1418 sarcoidosis and, 1419 transplantation and. See also Transplantation. liver, 1417-1418 lung, 1422 trapped lung and, 1422-1423, 1423f uremia and, 1419-1420, 1424.e4f yellow nail syndrome and, 1423, 1424.e5f Ex vivo lung perfusion, 1835 Eye involvement, 275.e1, 275.e3t Factor V Leiden mutations, 1002-1003 Factor Xa. See Activated factor X (factor Xa). Facultative progenitor cell pools, 258 Familial predisposition, 913-914 Family and Medical Leave Act (FMLA), 479 Family-based studies, 787, 788f Family histories, 268-269. See also Medical interviews. Family Smoking Prevention and Tobacco Control Act, 819 Farmer's lung disease (FLD), 1153. See also Hypersensitivity pneumonitis (HP). Fast-velocity vagal myelinated fibers, 499-500 Fat embolism, 1029.e1 Fatigue Assessment Scale, 1199 Fatigue, respiratory muscles, 82 FB. See Follicular bronchiolitis (FB). Federal Black Lung Program, 478.e1-478.e2 Feedback, controller, 1693 FEF. See Forced expiratory flow (FEF). FeNO. See Fractional exhaled nitric oxide (FeNO). Fetal chylothorax, 1452, 1455. See also Chylothorax. FEV, Forced expiratory volume (FEV) Fevers, inhalation, 1349-1350. See also Toxic exposures. Index Volume 1 pp 1-911 \u2022 Volume 2 pp 912-1850 Fine crackles, 271-272, 271t. See also Crackles. Fire-eater's lung, 1350 Five A's implementation strategies, 814, 815t Flail chest, 1714-1716, 1714f-1716f FLD. See Farmer's lung disease (FLD). Fleischer sign, 1009 Flooding, alveolar, 134-135, 1083, 1098, Fluid balance regulation, 92-110 Fluid clearance, 1537 Fluid protein concentrations, 1107 Fluid transport, 150-156. See also Alveolar epithelium. absorption, 150 active, 150-151 airway epithelial cells, alveolar vs. distal, 151-153, 152f alveolar edema mechanisms, 154-155 club cells (Clara), ciliated vs. nonciliated, 150 cyclic 3\u2032,5\u2032-adenosine monophosphate (cAMP) and, 151-154, 152f cystic fibrosis transmembrane regulators (CFTRs) and, 150-151, 152f future directions of, 156 ion transport, 151-153 models of, 150 overviews of, 150, 156b pathologic conditions and, 155-156, 155f Forced oscillation methods, 416.e1. See also Arterial blood gas measurements. Forced spirometry, 407-409, 408f, 407.e1 Forced vital capacity (FVC), 509 Foreign body removal, 384-385, 385f Formaldehyde exposures, 807, 1154 Four Rs (regeneration-repair-remodelingreplacement), 259 Fowler's method, 47, 47f FOX family transcription factors, 29 Fractional exhaled nitric oxide (FeNO), 1300 Fraction, deposition, 169 Fractures, rib, 520 Framing effect bias, 264t. See also Bias. FRC. See Functional residual capacity (FRC). Free-living ameba infections, 696-697, 514. Fungal balls, 671-672, 671f. See also Aspergillosis. Fungal infections, 1434-1436 Fusarium spp., 1153-1154 Futility, medical, 1811-1812 FVC. See Forced vital capacity (FVC). Gallium single-photon emission computed tomography scintigraphy, 360 Gap junctions, 135 GAPs. See GTPase-activating proteins (GAPs). Gas density, 412.e1. See also Arterial blood gas measurements. Gas exchange, 44-75 in clinical exercise testing, 438-439. See also Clinical exercise testing. age changes, 439 alveolar-arterial oxygen difference, 439 carbon dioxide, arterial partial pressures of, 438 carbon dioxide, end-tidal partial pressures of, 438 exercise-induced arterial hypoxemia, 439 gender differences, 439 obese vs. nonobese patients, 439 obstructive sleep apnea (OSA) and, 439. breath method and, 65 single-lung units and, 67-68, 68f steady-state method, 65-66 three-compartment model and, 70 ventilation-perfusion inequality, 61, 69-70, 69f ventilation-perfusion ratios, 70-73, 73f ventilation-perfusion relationships, 67 overviews of, 44, 60, 60f, 75b Gas flow through airways, 84-87 Gastroesophageal disorders, 1639-1642 Gastroesophageal reflux disease (GERD), 502, 1639-1641, 1640f Gastrointestinal (GI) agents, 708-709. See also See High-frequency ventilation (HFV). HHIPs. See Hedgehog. HHV8. See Human herpesvirus 8 (HHV8). HIFs. See Hypoxia inducible factors (HIFs). See Hypersensitivity pneumonitis (HP). HPI. See History of present illness (HPI). HPLC. See High-performance liquid chromatography (HPLC). HPS. See Hepatopulmonary syndrome (HPS). HPV. See Human papilloma virus (HPV). Indirect vs. direct antitussives, 511-512, 512f. See also Antitussives. Indoor vs. outdoor air pollution, 1331-1342 Induced cough, 497. See also Cough. Induced drug reactions, 1421-1422 Induction treatment results, 369.e1t Inductive tissue interactions, 25. See also",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Innate recognition, 187-192. See also Innate immunity. Innervation, 16f-17f. See also Lung anatomy. See also Cough. IOM. See Institute of Medicine (IOM). Ionic balance, 1529-1530 Ion transport, 151-153. See also Fluid transport. IOS. See Impulse oscillometry (IOS). IPA. See Invasive pulmonary aspergillosis (IPA). IPF. See Idiopathic pulmonary fibrosis (IPF). Iressa. See Gefitinib (Iressa). See Inspiratory reserve volume (IRV). ISAAC study. See International Study of See Langerhans cell histocytosis (LCH). LCNECs. See Large cell neuroendocrine carcinomas (LCNECs). LCQ. See Leicester Cough Questionnaire (LCQ). LDH. See Lactate dehydrogenase (LDH). Lead, 807 Leaky vs. tight junctions, 135 Left ventricular failure, 510 Legal and ethical justifications, 1809-1813, 1809t. See also End-of-life care. Low yield cigarettes, 814. See also Smoking hazards and cessation. LPSs. See Lipopolysaccharides (LPSs). LRIs. See Lower respiratory infections (LRIs). See Muscular dystrophy (MD). MDIs. See Metered-dose inhalers (MDIs). MDR. See Multidrug resistant (MDR). See also Ventilation. MIP. See Maximal inspiratory pressure (MIP). miRNA. See Micro-RNA (miRNA). MIST study. See Multicenter Intrapleural Sepsis",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "See Positron emission tomography (PET). PGD. See Primary graft dysfunction (PGD). PGS. See Posterior glottic stenosis (PGS). treatment of, 1448-1449 overviews of, 1439, 1460b pathophysiology of, 1439-1440, 1440f primary spontaneous (PSP), 1440-1444 clinical manifestations of, 1441 diagnosis of, 1441-1442, 1441f etiology of, 1440-1441 incidence of, 1440 recurrence rates of, 1442, 1443f treatment of, 1442-1444 See Peripheral nervous system (PNS). Podophyllotoxins, 1282. See also Chemotherapeutic agents. comparisons of, 1276t docetaxel, 1282 etoposide (VP-16), 1282 paclitaxel, 1282 teniposide, 1282 Podoplanin (D2-40), 1246 Point-of-care analyzers, 425.e10. See also Arterial blood gas measurements. Point-of-care tests, 614 POISE trial. See PeriOperative ISschemic Evaluation (POISE) trial. Poliomyelitis, 1696 Pollution, indoor vs. outdoor, 1331-1342 Polymer fume fever, 1349-1350 Polymodal sensory receptors, 499-501, 499f Polymorphonuclear leukocytes (PMNs), 1535 as effector mechanism, 193-195, 193f overviews of, 185, 185f Polymyositis/dermatomyositis (PM/DM), 1181-1183. See also Connective tissue diseases (CTDs). clinical features of, 1182 complications of, 1183 definition of, 1181 diagnosis of, 1181, 1181f-1182f diffuse lung disease in, 1182-1183, 1182f epidemiology of, 1181-1182 imaging for, 1182 pulmonary manifestations of, 1182-1183 risk factors for, 1181-1182 Pool sizes, 137f, 141-145, 141t. See also Pulmonary surfactant. Poor cooperation patterns, 431-432, 432t POPH. See Portopulmonary hypertension (POPH). Porphyria, 1727 Portopulmonary hypertension (POPH), 1645-1646, 1646f Positional cloning, 36 Positive end-expiratory pressure (PEEP). See also Positive-pressure ventilation. acute respiratory distress syndrome (ARDS) and, 147 alveolar recruitment and gas exchange, 1766 applied, 1763 auto-PEEP, 1763 benefits of, 1766 clinician-instigated (PEEPset), 76 definition of, 1761 detrimental effects of, 1766 inspiratory time prolongations, 1766 intrinsic (PEEPi), 87-89, 87f-88f, 1763 in chronic obstructive pulmonary disease (COPD), 87-89, 87f definition of, 87, 1763 dynamic, 88 in mechanical ventilation (MV), 88, 1761-1765 static, 87-88 motion equation and, 87 obesity and, 1720-1721. See also Obesity. RMs) in, 80 respiratory muscle atrophy in, 82 Positive-pressure ventilation, 1761-1777. See also Mechanical ventilation (MV). alveolar recruitment and gas exchange, 1765-1766 inspiratory time prolongations, 1766 positive end-expiratory pressure (PEEP), 1766. See also Positive endexpiratory pressure (PEEP). VS), 1761-1763 mechanical loads, 1766-1767 overviews of, 1761-1763, 1777b patient-ventilator interactions, 1767 physiological effects of, 1764-1767 alveolar ventilation, 1764 breaths, flow-targeted vs. pressuretargeted, 1764 intrinsic positive end-expiratory pressure (iPEEP), 1764-1765 motion equation, 1764 respiratory system mechanics, 1764-1765 ventilation mechanics, 1764-1765 ventilatory patterns, 1764-1765 pneumomediastinum and, 1536 positive end-expiratory pressure (PEEP), 1761-1765. See also Positive endexpiratory pressure (PEEP). pressure-time product (PTP), 1766-1767 ventilator-induced diaphragmatic dysfunction (VIDD), 1767 ventilator subsystems, 1763-1764 Post-cardiac injury syndrome (PCIS), 1420, 1424.e4f Post-coronary artery bypass surgery (CAGB), 1420-1421 Post embolic prophylaxis, 1022-1023 Posterior glottic stenosis (PGS), 893-894 Postnasal drip, 507 Postobstructive disorders, 867, 876.e4f Postobstructive pulmonary edema, 1100. See also Pulmonary edema. PPCs. See Postoperative pulmonary complications (PPCs). PPD. See Purified protein derivative (PPD). Preanalytic principles, 278-284. See also Microbiologic infection diagnoses. See also Pulmonary edema. alveolar barrier functions and, 1101 alveolar flooding in, 1083, 1098, 1098t high-altitude pulmonary edema and, 1099 increased, 1097-1101, 1097f, 1099t, 1108-1111 interstitial edema and, 1083, 1098t mechanisms of, 1099-1101, 1099t time index, 82 support cycle adjusters, 1776. See also Mechanical ventilation (MV). transdiaphragmatic, 1701, 1701f transmural protein osmotic, 1101 Pressurized metered-dose inhalers (MDIs), 170-171 Presynaptic voltage-gated calcium channels, 1697 Pretest probability, 263 Primary atypical pneumonia, 1436 Primary biliary cirrhosis, 1646-1647 Primary coccidioidal infection, 653-654. See also Coccidioidomycosis. Primary disease recurrences, 1847-1848 Primary effusion lymphoma (PEL), 1475-1476, 1476f Primary graft dysfunction (PGD), 1839-1840, 1839t Primary hyperalgesia, 516-517 Primary immunodeficiencies, 1624-1638 Primary limiting system identification, 454-456, 454f-455f, 455t Primary mediastinitis, 1507. See also Mediastinitis. Primary pleural malignancies, 964.e9f-964. e10f Primary pulmonary lymphomas, 966-969. See also Rare primary lung tumors. Proximal/distal renal tubular acidosis (RTA), 126. See also Renal tubular acidosis (RTA). Proximal renal tubular acidosis (RTA), 125. See also Renal tubular acidosis (RTA). PRRs. See Pattern recognition receptors (PRRs). PSB. See Protected specimen brush (PSB). Pseudochylothorax, 1455-1456. See also Pneumothorax. vs. chylothorax, 1451. See also Chylothorax. clinical manifestations of, 1456 definition of, 1455 diagnosis of, 1456 pathogenesis of, 1455-1456 treatment of, 1456 tuberculosis (TB) and, 1456, 1460.e2f Pseudoglandular stage, 22-24, 23f. See also Lung growth and development. Pseudomonas aeruginosa, 583 Pseudotumors, intrathoracic, 965, 974-977. See also Rare primary lung tumors. PSI scoring system, 564, 564.e1t Psittacosis (Chlamydophila psittaci), 708, 578.e2. See also Chlamydophila psittaci. PSP. See Primary spontaneous pneumothorax (PSP). Psychogenic cough, 510. See also Cough. Psychosocial training and support, 1826 PTCH1. See Patched 1 (PTCH1). PTCs. See Premature termination codons (PTCs). PTLD. See Posttransplantation. 1136t principles of, 1109, 1111-1112, 1112t vasodilators, 1110-1111 venous return, decreased, 1109-1110 ventilatory strategies, 1110 Pulmonary embolectomy, 1021-1022 Pulmonary embolism (PE). See also Pulmonary thromboembolism. diagnosis of, 1009-1016 exudative pleural effusion (PE) and, 1414-1415, 1414f natural history of, 1004-1005 vs. other embolism forms, 1029.e1-1029. vs. pulmonary arterial hypertension (PAH), 1031-1049. See also Pulmonary arterial hypertension (PAH). vs. pulmonary hypertension due to lung disease (PH-LD), 1050-1065 sarcoidosis-associated (SAPH), 1199-1200 in systemic lupus erythematosus (SLE), 1179 vasculitis in, 249.e1-249.e2 Pulmonary hypertension due to lung disease (PH-LD), 1050-1065 classification of, 1050, 1051t 2013 update, 1050 Clinical Classification of Pulmonary Hypertension, 1050, 1051t clinical manifestations of, 1058-1062 B-type natriuretic peptides (BNPs) and, 1062 chest radiography and, 1059-1060 computed tomography (CT) and, 1061, style modifications, 1062-1063 lung transplantation, 1063 lung-volume reduction surgery (LVRS), 1064 nitric oxide (NO), 1064.e2 oxygen therapy, 1063 phlebotomy, 1064 phosphodiesterase Type 5 antagonists, 1064.e1-1064.e2 polycythemia, 1064 prostacyclin, 1064.e1-1064.e2 prostacyclin analogues, 1064.e1-1064. e2 riociguat, 1064.e2 sleep-disordered breathing treatments, 1063 therapeutic strategies, 1062t Pulmonary lymphangioleiomyomatosis (LAM), 1455 Pulmonary meningothelial-like nodules, 976-977, 980.e19f Pulmonary parenchymal disease, 1173 Pulmonary rehabilitation, 1821-1831 adjuncts, recent, 1830-1831 home-based palliative care, 1830 noninvasive positive-pressure ventilation (NPPV), 1830 proportional assist ventilation, 1830 advance care planning and, 1830-1831 comprehensive program components, 1824-1829 breathing training, 1826-1827 chest physical therapy, 1826-1827 exercise training, 1824-1825 inspiratory muscle training, 1826-1827 integrated patient care, 1828 long term adherence and, 1828 nutritional support, 1826 oxygen assessments and therapies, 1827-1828, 1827t. See also Oxygen. patient education, 1825-1826, 1825t physical activity promotion, 1829 program organization and resources, See Pulmonary surfactant. Pulmonary surfactant, 134-149. See also Alveolar epithelium. abnormalities in lung disease, 146-148 alveolar cells TI, 135-138, 136f, 138t, 139f TII, 138-140, 139f alveolar epithelial intercellular junctions, 135 alveoli, 135 composition of, 137f, 141-145, 141t surfactant protein B (SP-B), 143-144 surfactant protein C (SP-C), 144 surfactant protein D (SP-D), 144-145 extracellular processing of, 145-146, 146f overviews of, 134-135, 148b phospholipids, metabolic trafficking of, 145-146, 146f physiologic functions of, 140-141, 140f-141f pool sizes, 137f, 141-145, 141t references for, 148 secretion, 145-146 Pulmonary thromboembolism, 1001-1030 chronic thromboembolic pulmonary hypertension (PH), 1023 diagnosis of, 1024-1026, 1025f-1026f epidemiology of, 1023 treatment of, 1026-1029, 1027f, 1029f clinical manifestations of, 1005-1006 diagnosis, deep venous thrombosis (DVT), 1006-1009, 1029.e4f clinical prediction rules, 1008-1009, 1009t computed tomography (CT), 1008, 1029. e8f contrast venography, 1006-1007, 1007f D-dimer testing, 1008 duplex ultrasonography, 1007-1008, 1007f, 1029.e3f magnetic resonance imaging (MRI), 1008 diagnosis, pulmonary embolism (PE), 1009-1016 chest radiographs, 1010f, 1029. e5f-1029.e6f clinical prediction rules, 1014-1016, 1015f, 1015t Pulmonary function testing (Continued) Pulmonary hypertension due to lung disease (PH-LD) (Continued) respiratory muscles, 82 hysteresis, 79-80, 80f integration, lung-chest wall mechanics, 82-83, 83f Laplace's law, 79, 79f lung connective tissue network, 79 oxygen cost of breathing, 90.e1f plateau pressures, 84 pleural pressures, 83-84 recruitment maneuvers, 80, 80f respiratory muscles, 80-81, 81f stress adaptation, 79-80 total respiratory system compliance, 83 See also Extrapulmonary disorders. vs. solid organ transplantation, 1612-1623 Slowly growing mycobacteria (Continued) Smoking hazards and cessation (Continued) Stent placement, 387-388, 388f Stepwise management, 781-782 Stereotactic ablative radiotherapy (SABR), 368-370 Sternal dehiscence, 1510.e8f St. George's Respiratory Questionnaire, 489 Stop-and-shoot method, 304-305. See also Computed tomography (CT). Strain, 84.e1 Stratification, risk, 448-449, 449f. See also Risk assessments. Stratosphere sign, 349t Streptococcus pneumoniae, 584 Streptomycin, 628.e13-628.e18, 628. Stroke volume, 438. See also Volumes. Strong vs. weak ions, 112 Strongyloidiasis, 685-687, 686f Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatment (SUPPORT), 1807 Styrene exposures, 1154 Subarachnoid pleural fistula, 1413 Subcutaneous and skin lesions, 275.e1, 275. Subgross and gross organization, 3-6, 4f-5f, 5t. See also Lung anatomy. Submucosal lesions, 948 Suboptimal specificity, 561 Substance effects, 57 Substance P-mediated effects, 1351-1352 Sugar tumors, 976-977, 1000, 1000f Sulfur dioxide exposures, 1347 Sulfur mustard (mustard gas), 1348 Superinfection pneumonia, 569 Superior sulcus, 964.e11f Superior sulcus (pancoast) tumors, 957-959, 958f, 964.e11f Superoxide, 155 SUPPORT. See Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatment (SUPPORT). Suppression therapies, cough, 511-513, 511t. See also Cough. Supratherapeutic activated partial thromboplastin time (aPTT), 1018 Surface-active material. See Pulmonary surfactant. Surface forces, 79, 79f Surface tension, low, 140 Surfactant aggregate, large (LA), 145-146 alveolar, 79, 79f proteins, 141-145, 141t surfactant protein A (SP-A), 142-143 surfactant protein B (SP-B), 143-144 surfactant protein C (SP-C), 144 surfactant protein D (SP-D), 144-145 pulmonary, 134-149. See also Alveolar epithelium; Pulmonary surfactant. abnormalities, 146-148 alveolar epithelial intercellular junctions, 135 alveolar TI cells, 135-138, 136f, 138t, 139f alveolar TII cells, 138-140, 139f alveoli, 135 composition of, 137f, 141-145, 141t surfactant protein C (SP-C), 22 extracellular processing of, 145-146, 146f overviews of, 134-135, 148b phospholipids, metabolic trafficking of, 145-146, 146f physiologic functions of, 140-141, 140f-141f pool sizes, 137f, 141-145, 141t references for, 148 secretion, 145-146 Surgical approach selection criteria, 466 Surgical debulking, 1473 Susceptibility tests, antimicrobial, 292 SUVs. See Standard uptake values (SUVs). Sv. See Sieverts (Sv). SV40. See Simian virus (SV40). Swallowing disorders, 889-890 dysphagia evaluations, 890 epidemiology of, 889 symptoms of, 889-890 treatment of, 890 Sweat gland dysfunction, 840 Swine-origin (H1N1) virus, 556.e4f SWTs. See Shuttle walk tests (SWTs). Symmetrical cell division, 257 Symptomatic antitussives, 511. See also Antitussives. Synchrony optimization, 1775-1777. See also Mechanical ventilation (MV). Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 962 Syndromic order sets, 279 community-acquired pneumonia, 279t-280t hospital-acquired pneumonia, 281t ventilator-associated pneumonia, 281t Synovitis, 1183 Synthesis, mucin, 158, 158t Synthetic pentasaccharides, 1017 Synthetic peptides, 368 Syphilitic myelinolysis, 1694 System biology, cancers, 922-923 Systemic lupus erythematosus (SLE), 1178-1179 acute lupus pneumonitis in, 1178 definition of, 1178 diagnosis of, 1178, 1178t diffuse alveolar hemorrhage in, 1179, 1187.e5f diffuse interstitial fibrosis, 1187.e5f diffuse lung disease in, 1178 epidemiology of, 1178 extrapulmonary restriction in, 1178-1179, 1179f interstitial pneumonia in, 1178 pleural disease in, 1179 pulmonary hypertension (PH) in, 1179 pulmonary manifestations of, 1178-1179, 1178t risk factors for, 1178 Systemic oxygenation, 1542 Systemic sclerosis (SSc), 1165-1173. See also Connective tissue diseases (CTDs). aspiration pneumonia in, 1173 chemically-induced scleroderma-like disorders, 1166-1167 classification of, 1165 clinical features of, 1168 complications of, 1173 definition of, 1165 diagnosis of, 1165, 1167t epidemiology of, 1165-1166 imaging for, 1168-1169, 1168f interstitial pulmonary fibrosis in, 1167-1168, 1168f microaspiration in, 1173 mild, 1187.e1f moderate, 1187.e1f pleural disease in, 1173 prognosis for, 1170-1171 progressive, 1187.e2f pulmonary manifestations of, 1167-1172 pulmonary parenchymal disease in, 1173 pulmonary vascular disease in, 1172-1173 risk factors for, 1165-1166 treatment of, 1171-1172 T790M mutations, 913-914 Tachypnea, 270, 270f Tadalafil (Adcirca), 1046 Talc insufflation, 1471 pleurodesis, 399, 399f, 517 Tarceva. See Erlotinib (Tarceva). Targeted biologic agents, 744-745 Targeted chemotherapeutic agents, 1282. See also Chemotherapeutic agents. erlotinib, 1284 immunomodulatory agents, 1284-1285 monoclonal antibodies, 1283-1284. See also Monoclonal antibodies. tyrosine inhibitors, 1284. See also Tyrosine inhibitors. erlotinib (Tarceva), 1284 gefitinib (Iressa), 1284 imatinib (Gleevec), 1284 tyrosine kinase inhibitors, 1284 TB. See Tuberculosis (TB). TBBs. See Transbronchial biopsies (TBBs). TBIs. See Traumatic brain injuries (TBIs). TBNAs. See Transbronchial needle aspirations (TBNAs). T cells, 206-208. See also Lymphocytes. T-cell antigen receptors (TCRs), 206-207 T-cell factor/lymphoid enhancer factor (TCF-LEF), 27-28 TCF-LEF. See T-cells. TCRs. See T cells. TDM. See Trehalose dimycolate (TDM). Tear gas agents, 1348 Temozolomide, 1280 Temporal trends, 927, 928f, 929t. See also Lung cancers. Temporary impairment, 470 Teniposide, 1282 Tension pneumothorax, 1449-1450. See also Pneumothorax. clinical manifestation of, 1449-1450 definition of, 1449 Tension regulation, 111-112 Terbinafine, 662t-665t, 667 Terminally differentiated cells, 257 Terminal respiratory units, 7f, 10f, 12-16, 13f-15f. See also Lung anatomy. Terrorism. See Bioterrorism. Tests, diagnostic, 278-298. See also Laboratory diagnostic tests. T factor, 362. See also Tumor-node-metastasis (TNM) staging. TFG-\u03b21. See Transforming growth factor-\u03b21 (TFG-\u03b21). TGF-\u03b2 superfamily. See Transforming growth factor-\u03b2 (TGF-\u03b2) superfamily. Therapeutic aerosols, 170-171. See also Aerosol deposition and clearance. developments in, 171 dry powder devices, 170, 170f generation of, 169 jet nebulizers, 171, 172f pressurized metered-dose inhalers (MDIs), 170-171 Therapeutic bronchoscopy, 383-392. See also Bronchoscopy. advantages vs. disadvantages of, 383, 384t cautions for, 384t central airway obstruction and, 384-390 intrabronchial valve placement, 392 historical perspectives of, 383 overviews of, 383, 392b Therapeutic hypercapnia, 1529. See also Hypercapnia. Therapeutic hypocapnia, 1529 Thermal ablation, lung cancers, 344-345, 345t Thin-walled cystic lung disorders, 1259. e5f-1259.e6f Thirst and hunger management, 1818 Thoracic spine abnormalities, 405 Thoracoplasty, 1711-1712, 1711f-1712f Thoracoscopic biopsies, 1471. See also Biopsies. equipment for, 394-395, 394f-395f historical perspectives of, 393-394 indications for, 395-396, 396t overviews of, 393, 406b patient preparation for, 397 pleural space access and, 397 talc pleurodesis, 399, 399f techniques for, 394, 398-399, 398f vs. video-assisted thoracic surgery (VATS), 393-394, 405-406 Thoracoscore, 458-459 Thoracotomy, 1467 Three-compartment model, 70 Three-zone model, 53-54, 53f Threshold identification, 452-454, 453f Throat-clearing, 507 Thrombin inhibitors, 1017-1020 Thromboembolism, 1001-1030 chronic thromboembolic pulmonary hypertension (PH), 1023 diagnosis of, 1025f-1026f epidemiology of, 1023 treatment of, 1026-1029, 1027f, 1029f clinical manifestations of, 1005-1006 diagnosis, deep venous thrombosis (DVT), 1029.e4f clinical prediction rules, 1008-1009, 1009t computed tomography (CT), 1008, 1029. e8f contrast venography, 1006-1007, 1007f D-dimer testing, 1008 duplex ultrasonography, 1007-1008, 1007f, 1029.e3f magnetic resonance imaging (MRI), 1008 diagnosis, pulmonary embolism (PE), 1009-1016 chest radiographs, 1010f, 1029. e5f-1029.e6f clinical prediction rules, 1014-1016, 1015f, 1015t computed tomography pulmonary angiography (CTPA), 1011-1013, 1012f D-dimer testing, 1014 echocardiography, 1010, 1029.e6f lower extremity venous evaluations, 1013-1014 pulmonary angiography, 1014, 1014f single-photon emission computed tomography (SPECT), 1013 single-photon emission computed tomography-ventilation perfusion imaging (SPECT V/Q), 1013 standard laboratory evaluations, 1009-1010 thrombin inhibitors, 1017-1018 ventilation-perfusion scanning, 1010-1011, 1011f, 1029.e7f management of, 1018-1020 activated factor X (factor Xa) inhibitors, 1019-1020 fondaparinux, 1019 inferior vena cava filters, 1020, 1020f low-molecular-weight heparin (LMWH), PE), 1004-1005 vs. other embolism forms, 1029.e1-1029. e2 air embolism, 1029.e1, 1029.e8f amniotic fluid embolism, 1029.e2 cancer cell embolism, 1029.e2 fat embolism, 1029.e1 methyl methacrylate pulmonary embolism, 1029.e10f noninfectious vasculitic-thrombic complications, 1029.e2 overviews of, 1029.e1 pulmonary artery embolism, 1029.e2 schistosomiasis, 1029.e1 septic embolism, 1029.e2, 1029.e9f in situ thrombosis, 1029.e2 overviews of, 1001-1002, 1029b pathogenesis of, 1002-1003 post embolic prophylaxis, 1022-1023 prevention of, 1016-1018 activated factor X (factor Xa) inhibitors, 1017-1018 fondaparinux, 1017 fundamentals of, 1016 low-dose unfractionated heparin, 1016-1017 low-molecular weight heparin (LMWH), 1016-1017 pneumatic compression devices, 1017 thrombin inhibitors, 1017-1018 warfarin, 1017 references for, 1029 resolution vs. thromboembolism persistence, 1023 risk factors of, 1002-1003, 1002t Thymic stromal lymphopoietin (TSLP), 719-720, 719f Thyroid transcription factor-1 (TTF-1), 28-29, 140, 147 TI cells, alveolar, 135-138, 136f, 138t, 139f Tidal flow-volume curves, 419.e1 Tight vs. leaky junctions, 135 TII alveolar cells, 138-140, 139f TIMP-3. See Tissue inhibitor of metalloproteinase-3 (TIMP-3). TIPS. See Transjugular intrahepatic portal systemic shunts (TIPS). Tissue eosinophilia, 1241-1242 Tissue inhibitor of metalloproteinase-3 (TIMP-3), 1247.e1 Tissue interactions, 25-26, 25f. See also Lung growth and development. bronchopulmonary sequestration, 25, 25f FOX family transcription factors, 29 inductive, 25 vascular endothelial growth factors (VEGFs) and, 29 Tissue resident dendritic cells (DCs), 201-203, 203f. See also Dendritic cells (DCs). Tissue-specific stem cells, 257-258. See also Stem cells. TLC. See Total lung capacity (TLC). TLRs. See Toll-like receptors (TLRs). TNBs. See Transthoracic needle biopsies (TNBs). TNF-\u03b1. See Tumor necrosis factor-\u03b1 (TNF-\u03b1). TNM staging. See Tumor-node-metastasis (TNM) staging. Tobacco smoking hazards and cessation, 807-821. See also Smoking hazards and cessation. Toll-like receptors (TLRs), 189, 719-720 Tonsillar enlargement, chronic, 510 Topographic inequality, 48. See also Inequality. Topotecan, 1283 Total lung capacity (TLC), 76-77, 1719-1720, 1720f, 1720t Total pulmonary vascular resistance, 51 Total respiratory system compliance, 83 Touch-sensitive mechanosensors, 500-501, 504f Toxic exposures, 1343-1353 chronic sequelae of, 1345 inhalation fevers, 1349-1350 concentrated animal feeding operations (CAFOs) and, 1349-1350 Legionella spp. and, 1349-1350 organic dust toxic syndrome (ODTS), 1349-1350 polymer fume fever, 1349-1350 signs and symptoms of, 1349 management principles for, 1344-1345 overviews of, 1343, 1353b pathogenesis of, 1343-1344 references for, 1353 residual effects of, 1345 response patterns, 1343-1344, 1344t irritant inhalation, 1343-1344 other irritants, 1344 water-soluble irritants, 1344 specific exposures, 1345-1353, 1346t military/crowd control agents, 1347-1348. See also Military/crowd control agents. nitrogen, oxides of, 1347 ozone, 1347 paraquat herbicide, 1350-1351 pharmacologic syndromes, 1351-1352 pyrolysis, 1351 smoke inhalation, 1351 sulfur dioxide, 1347 toxic metals, 1348-1349. See also Toxic metal exposures. Toxins as bioterrorism agents, 708-709 environmental aerosols and, 180-181 Toxoplasmosis, 695-696 TP53 mutations, 914-917 TPE. See Tropical pulmonary eosinophilia (TPE). Tracheal lung sounds, 271-272, 271t Tracheobronchial aspergillosis, 675-676, 675f-676f. See also Aspergillosis. Tracheobronchial disease, 1180-1181 Tracheobronchial malacia, 514.e1f Trafficking, metabolic, 145-146, 146f Tram tracks, 869, 870f Transbronchial biopsies (TBBs), 376-377, 377f. See also Biopsies. Transbronchial needle aspirations (TBNAs), 377, 377f-378f. See also Diagnostic bronchoscopy. Transcription factor-1. See Thyroid transcription factor 1 (TTF-1). Transcription regulation, 28-29. See also Molecular regulation. definition, 28 FOX family transcription factors, 29 GATA6, 29 Gli genes, 29 NXX2-1, 28-29 SOX family transcription factors, 29 Transcutaneous oxygen electrodes, 425.e9 Transcytosis, 150 Transdiaphragmatic pressure, maximum, 433. e1 Transducers, 349. See also Ultrasonography. Transfer capacity, 420-422 Transforming growth factor-\u03b21 (TFG-\u03b21), 155 Transforming growth factor-\u03b2 (TGF-\u03b2) superfamily, 27, 138-139, 192, 1033 Transient receptor potential cation channel,. See Transient receptor potential (TRP) channels. Transient receptor potential cation channel, subfamily A, member 1 (TRPA1), 501 Transient receptor potential (TRP) channels, 501 Transient receptor potential vanilloid-1 (TRPV1), 501 Transit-amplifying cells, 257 Transjugular intrahepatic portal systemic shunts (TIPS), 1412 Translational readthroughs, 845-846 Transmission routes, bioterrorism agents, 699 Transmural pressure, 78, 78f Transmural protein osmotic pressure, decreased, 1101 Transplantation. See also Extrapulmonary disorders. heart-lung transplantation (HLT), 1836 lung, 1832-1849. See also Lung transplantation. allocation system and guidelines for, 1833-1834, 1834t artificial lung technologies, 1834-1835, 1834f candidate selection criteria for, 1832-1833 complications of, 1839-1848 donor selection criteria, 1835, 1835t future directions of, 1848-1849 immunosuppressive medications, 1836-1839, 1838t indications of, 1832-1833 lung preservation, 1835-1836 overviews of, 1832, 1848b posttransplantation management, 1836-1839 pulmonary function testing of, 434 references for, 1849 referral and listing timing for, 1833 rejection complications, 424, 1843-1846 retransplantation, 1848 surgical techniques for, 1836 pulmonary function testing of, 434 stem cell vs. solid organ, 1612-1623 Transport blood-gas, 58-60 carbon dioxide, 59-60, 60f definition of, 58 oxygen, 58-59, 59f fluid, 150-156. See also Alveolar epithelium. absorption, 150 active, 150-151 airway epithelial cells, alveolar vs. distal, 151-153, 152f alveolar edema mechanisms, 154-155 club cells (Clara), ciliated vs. nonciliated, 150 cyclic 3\u2032,5\u2032-adenosine monophosphate (cAMP) and, 151-154, 152f cystic fibrosis transmembrane regulators (CFTRs) and, 150-151, 152f future directions of, 156 ion transport, 151-153 models of, 150 overviews of, 150, 156b pathologic conditions and, 155-156, 155f references for, 156 regulation of, 153-154 Transthoracic lung aspiration, 564 Transthoracic needle biopsies (TNBs), 332-338. See also Biopsies. complications of, 338 imaging guidance selection criteria, 334, 334f Toxic exposures (Continued) Urinothorax, 1413 URIs. See Upper respiratory infections (URIs). VA. See Veterans Administration (VA). Valvular heart disease, 520 Vanadium exposures, 1349 Vanadyl phosphate exposures, 1349 VAP. See Ventilator-associated pneumonia (VAP). Varenicline, 818 Variant adenocarcinomas, 227-228. See also Adenocarcinomas. Varicella, 528-529, 529t Varicella-zoster virus (VZV), 552-556, 555f, 556.e7f-556.e8f Varicoid bronchiectasis, 853-854, 854f VAS. See Visual analogue scale (VAS). Vascular abnormalities, 1081-1095 Vascular cannulas, 1796 Vascular congestion effects, 1083, 1098-1099, 1098t Vascular disease, 1172-1173 Vascular embolic metastasis, 989-990 Vascular endothelial growth factors (VEGFs), 28-29, 1246 lymphangiogenesis induction and, 1246. See also Lymphangioleiomyomatosis (LAM). VEGF-C, 1246 VEGF-D, 1246, 1255 VEGFR-3, 1246 Vascular impairment, 1738-1739 Vascular resistance, 50-53 Vascular sarcomas, 972-974. See also Sarcomas. Vasculature, pulmonary, 1530-1533 Vasculitic-thrombic complications, noninfectious, 1029.e2 Vasculitis, 1066-1080 classification of, 1066, 1067t clinical disorders, 1072-1075, 1073t eosinophilic granulomatosis with ventilatory oxygen equivalents, 438 Ventilatory support, 1703-1704, 1703t, 1704f full-time, 1705 nocturnal, 1704 Ventilatory therapy strategies, 1110 Ventilatory threshold identification, 452-454, 453f Vesicular lung sounds, 271-272, 271t Veterans Administration (VA), 478, 478.e3 Vicious cycle concept, 855-858 Video-assisted thoracic surgery (VATS) herpes simplex virus (HSV), 540-541 influenza virus, H1N1 (swine-origin), 556.e4f influenza virus, seasonal, 541-546, 543f-544f, 544t, 556.e3f-556.e4f influenza virus, type A, 530, 556. e3f-556.e4f influenza virus, type B, 530 measles virus, 546-548 metapneumoviruses (MPVs), 548-549 parainfluenza viruses, 549-550 respiratory syncytial virus (RSV), 550-552, 556.e6f rhinoviruses (RVs), 552-554, 553f varicella-zoster virus (VZV), 552-556, 555f, 556.e7f-556.e8f pleural infections and, 1436 references for, 556 smoking and, 810, 810t steeple sign in, 556.e1f transmission of, 527 Virtual bronchoscopic navigation, 380. See also Diagnostic bronchoscopy. Virulence factors, 593 Visceral larva migrans (VLM), 688 Visceral pain, 516 Visceral perforations, 1503-1505, 1504f-1505f Viscerosomatic convergence, 518 Visual analogue scale (VAS), 489-490, 489f, 517 VLM. See Visceral larva migrans (VLM). Vocal cord dysfunction, 891-892 Vocal cord dysfunction (VCD), 747-748 Vocal cord paralysis, 892-893 bilateral, 893 unilateral, 892 Voiced phase, 497. See also Cough. Voice-generated sounds, 273 Voltage-gated channels calcium, 1697 sodium, 501 Volume plethysmography, 413-415, 414f Volume (open-type) plethysmography, 435.e2f, Voluntary ventilation, maximum, 433.e1 Vomiting management, 1818 von Hippel-Lindau syndrome, 1244 VP-16. See Etoposide (VP-16). VS. See Volume support (VS). VTE. See Venous thromboembolism (VTE). VV-ECMO. See Veno-venous extracorporeal membrane oxygenation (VV-ECMO). VZV. See Varicella-zoster virus (VZV). Wall, chest. See Chest wall. Warfarin, 1017, 1040-1041 Wash-down, 1097 Washings, bronchial, 376. See also Diagnostic bronchoscopy. Wasted ventilation, 1098 Water measurements, lung, 1107-1108 Waveforms, cough, 498f. See also Cough. Wave speed theory, 86-87 WEA. See Work-exacerbated asthma (WEA). Weakness, ICU-related, 1699-1700 Weak vs. strong ions, 112 Wedge pressure, 51 Wegeners granulomatosis. See Granulomatosis with polyangiitis. Weibel model, 44-45, 45f Wells model, 1014-1016, 1015f, 1015t Westermark sign, 1009 Wheezer patterns, 716-717 Wheezes, 271t, 272-273 WHO. See World Health Organization (WHO) classifications. Whole-person impairment, 469 Williams-Campbell syndrome, 855, 863-864, 864f, 876.e2f Windows, acoustic, 349t Wingless (Wnt) family, 26-28 Withdrawal symptoms, nicotine addiction, 813 Withholding/withdrawal of life-sustaining therapies, 1818-1819. See also End-of-life care. Ventilatory failure, acute (Continued)",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "acute inflammatory polyneuropathy, 1695 -1696 Charcot Marie Tooth, 1727 immunologic, 1727 Neurosarcoidosis, 1200 -1201 . See also Sarcoidosis. Neurotoxicants, 1348 Neutrophils, 725, 856-857, 857f, 1536 -1537 ",
            "cite_spans": [
                {
                    "start": 35,
                    "end": 39,
                    "text": "1695",
                    "ref_id": null
                },
                {
                    "start": 40,
                    "end": 45,
                    "text": "-1696",
                    "ref_id": null
                },
                {
                    "start": 46,
                    "end": 71,
                    "text": "Charcot Marie Tooth, 1727",
                    "ref_id": null
                },
                {
                    "start": 72,
                    "end": 89,
                    "text": "immunologic, 1727",
                    "ref_id": null
                },
                {
                    "start": 90,
                    "end": 112,
                    "text": "Neurosarcoidosis, 1200",
                    "ref_id": null
                },
                {
                    "start": 113,
                    "end": 118,
                    "text": "-1201",
                    "ref_id": null
                },
                {
                    "start": 130,
                    "end": 163,
                    "text": "Sarcoidosis. Neurotoxicants, 1348",
                    "ref_id": null
                },
                {
                    "start": 164,
                    "end": 201,
                    "text": "Neutrophils, 725, 856-857, 857f, 1536",
                    "ref_id": null
                },
                {
                    "start": 202,
                    "end": 207,
                    "text": "-1537",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Neuropathies"
        }
    ]
}